Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Brittain, Rodney
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease	Terminated	3	1125	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	12/24	12/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease	Active, not recruiting	2/3	225	Canada, US	Piromelatine 20 mg, Neu-P11, Placebo	Neurim Pharmaceuticals Ltd., Syneos Health	Alzheimer's Disease	06/25	06/25
El-Aghil, Madie
NCT05217927 / 2021-005239-22: Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens	Completed	4	698	Europe, Canada, US	Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing	Pfizer, Biohaven Pharmaceuticals Holding Company Limited, Pfizer Inc.	Migraine	10/24	12/24
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24